What We Do
Discover
new approaches to developing vaccines and other means of preventing HIV.
Accelerate
translational and clinical research through our laboratories in the U.S., India, and the U.K.
Build Capacity
in-country for researching vaccine candidates while strengthening local public health and scientific expertise.
Partner
with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.
Share
IAVI’s resources with other innovators to help the HIV community as a whole succeed.
Extend
IAVI’s core capabilities to solving disease prevention and treatment challenges.
Latest News from IAVI
IAVI Report: Antibodies & Optimism
Scientists are more optimistic than ever about developing HIV vaccines and antibody-based products.
Donor Spotlight: Danida
IAVI recognizes the Danish government for its continued commitment to HIV vaccine research and applauds the dedication of the Danish Ministry of Foreign Affairs to global health research and development.
Antibody-based HIV Prevention: Preparing for Success
New partnership aims to make antibody prophylaxis for HIV more feasible and affordable.
IAVI and Serum Institute Aim for Antibody Access
Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access
New Hope for TB Vaccines
After decades of research, renewed promise emerges for developing vaccines against the world’s deadliest infectious disease.
Why Do We Need an HIV Vaccine?
IAVI staff explain why an HIV vaccine is the best way to end to the epidemic.
Publications
Kenya HIV & AIDS Research Agenda
©2018 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative, IAVI, and the IAVI logo
are trademarks of the International AIDS Vaccine Initiative, Inc.
